Lynx Augments Its Intellectual Property Portfolio.
HAYWARD, Calif.--(BUSINESS WIRE)--Jan. 20, 2000
Lynx Therapeutics, Inc. (Nasdaq: LYNX) announced today that it has made two important additions to its genomics intellectual property portfolio.
The first is patent No. 6,013,445, recently issued by the U.S. Patent Office, broadly covering Lynx's use of encoded adaptors in its Massively Parallel Signature Sequencing (MPSS(R)) technology. The other is the acquisition of an exclusive worldwide license to a pioneering molecular tagging technology from Harvard Medical School.
This license, which includes U.S. patent 5,149,625 and several foreign counterparts, covers technology invented by Drs. George M. Church and Stephen Kieffer-Higgins. The patents describe materials for attaching oligonucleotide tags to polynucleotides, such as DNA sequencing templates.
&uot;We are pleased to announce these recent additions to our intellectual property portfolio, which now includes an impressive total of 49 issued patents worldwide in the areas of genomics, DNA analysis, and DNA chemistry,&uot; said Dr. Norrie Russell, President and Chief Executive Officer of Lynx. &uot;Encoded adaptors are a key element of our MPSS(R) technology since they increase the efficiency of the method by almost an order of magnitude. The license from Harvard Medical School is also very important. In addition to providing world-wide protection in an important area of DNA tagging, it also broadens the reach of Lynx's existing patents covering the Company's Megaclone(TM) technology. Megaclone(TM) technology, which depends on means for tagging DNA in a manner such as to bind it to micro-beads, enables the simultaneous manipulation and analysis of very complex mixtures of millions of DNA molecules or fragments.&uot;
Lynx Therapeutics, Inc. has developed unique, proprietary technologies for handling and/or analyzing, simultaneously, the DNA molecules or fragments in complex biological samples. Applications include the identification of genes differentially expressed between samples, the characterization of gene expression within a sample, and a novel, highly efficient means for scoring (genotyping) large numbers of genetic markers or single nucleotide polymorphisms (SNPs), simultaneously, against very large numbers of genomes. Lynx is currently commercially applying its technologies through service agreements with pharmaceutical and other companies. For more information, visit Lynx's web site at www.lynxgen.com.
Statements included in this press release that are not historical in nature, are &uot;forward-looking statements&uot; within the meaning of the &uot;safe harbor&uot; provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements due to the risks and factors identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 1998.
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 20, 2000|
|Previous Article:||Dynamics Research Corporation Names New Chief Financial Officer.|
|Next Article:||Cambior Responds to bid Announced by Aur Resources Inc.|